SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Who pays when an AI agent tries again?

Brandlight helps enterprise marketers manage how AI recommends their brand

BlueGreen Water Technologies turns algae blooms into large-scale carbon removal

Taboola to acquire Dianomi for up to £27 million as it pushes deeper into finance advertising

Buzz

Most popular

Daily

Weekly

1

Serbia opens Israeli drone factory as defense ties with Elbit deepen

2

The man who helped build Palo Alto’s Cortex is leaving the company

3

“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B

4

How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit

5

Sayeret Matkal veterans raise $22 million to teach the world English with AI

PhaseV

4 stories about PhaseV

Promising HealthTech

WATCH: CTech's most promising healthtech startups

Here's everything you need to know about Sensi.ai, Briya Labs, PhaseV, Zorro, and DeepCure

כנס ניו יורק - ד"ר רביב פרילוק מנכ"ל PhaseV

PhaseV raises $50 million Series A to rethink how drugs get to market

With over 30 global customers, the AI startup targets inefficiencies in clinical trials.

CTech NY Conference Dr Raviv Pryluk

Here’s how PhaseV uses AI to optimize clinical trials to speed clinical development

27.03.25|James Spiro

CEO and Co-Founder Dr. Raviv Pryluk spoke to CTech after being named as one of the Top 10 Israeli startups to watch out for in 2025 at Calcalist’s Mind The Tech conference in New York.

Raviv Pryluk PhaseV

PhaseV raises $15 million to optimize clinical trials with causal machine learning

The Israeli startup detects hidden signals in clinical data and extracts actionable insights for planning the next steps